Web Results

Intensive Dose-Dense Compared With High-Dose Adjuvant ...

jco.ascopubs.org/content/25/13/1677.long

May 1, 2007 ... ... MD; Mayo Clinic, Rochester, MN; University of California-Davis, Sacramento; and The .... STAMP V consisted of cyclophosphamide 1.5 g/m<sup>2</sup>/d, carboplatin 200 .... Clifford Hudis, Amgen, Bristol-Myers Squibb Research Funds: Julie R. ... Roche H, Viens P, Biron P, et al: High-dose chemotherapy for breast ...

Lithium plus valproate combination therapy versus monotherapy for ...

www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61828-6/fulltext?rss=yes

Dec 23, 2009 ... ‡Repeated measures analysis of variance (combination vs monotherapy). ..... Clifford, Robert Croos, Jane Da Rosa Davis, Lalitha De Silva, Savitha Eranti, ... Ali Carre, Julia Cartright, Julie Chalmers, Apa Chisuse, Phil Davison, David ... boards with AstraZeneca, Bristol-Myers Squibb, Lilly, Janssen Cilag, ...

Basic Research Workshop - AASLD

www.aasld.org/sites/default/files/documents/2015/Syllabi/BRW Syllabus.pdf

Nov 15, 2015 ... Gary L. Davis, MD, FAASLD (Scientific Program Committee and ... Grant/ Research Support: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Merck ... Julie Deal .... Colombo et al, Annu Rev Cell dev Biol 2014, 30:255. ..... Rautou PE, Bresson J, Sainte-Marie Y, Vion AC, Paradis V, Renard JM, Devue C, et al.

Phase 1B, randomized, double-blind, dose-escalation trial of CPG ...

onlinelibrary.wiley.com/doi/10.1002/hep.21773/full

Oct 10, 2007 ... Dr. Davis owns stock in and holds intellectual property rights to Coley Pharmaceuticals Group, Inc. Dr. Bacon ... He also provides research support to Roche Laboratories, and Bristol-Myers Squibb. .... Julie A. Lekstrom-Himes, ...... 8 Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, et al.

Notice of Hearing Session

www.uniset.ca/lloydata/LL_multidistrict.pdf

Apr 14, 2004 ... Motion of plaintiffs Madhavi Parvathaneni, et al., for centralization of the following actions in the ..... Elizabeth Davis, et al. v. Life Insurance ... Bristol-Myers Squibb Co., et al., C.A. No. 3:03-1668 ..... Julie K. Pullin v. Wyeth, et al.

Full Text (PDF) - Proceedings of the National Academy of Sciences

www.pnas.org/content/112/30/E4085.full.pdf

Jul 13, 2015 ... Cilag, and Bristol-Myers Squibb and speaker's fees from ... activation in the ventral striatum (VS) during reward anticipation. ... reduced ethanol sensitivity in ics mutants was not caused by al- ... Ojelade et al. ...... McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL (2003) Spatiotemporal rescue of.

Rsu1 regulates ethanol consumption in Drosophila and humans

www.pnas.org/content/112/30/E4085.long

Jul 28, 2015 ... The results of association analyses between VS and RSU1 gene are summarized. ROI ..... Janssen-Cilag, and Bristol-Myers Squibb and speaker's fees from AstraZeneca, .... McGuire SE,; Le PT,; Osborn AJ,; Matsumoto K,; Davis RL .... Bierut LJ, et al., Gene, Environment Association Studies Consortium.

JAMA Network | JAMA | Three- vs Four-Drug Antiretroviral Regimens ...

jama.jamanetwork.com/article.aspx?articleid=203172

Aug 16, 2006 ... ObjectiveTo compare the safety/efficacy of 3-drug vs 4-drug regimens for initial treatment of HIV-1 infection. ... patients could substitute stavudine (Zerit, Bristol- Myers Squibb) for zidovudine, .... *Details reported in Gulick et al. ...... Jr, MD ( University of Minnesota); Paula Potter, RN, BSN, Julie Hoffman, RN, ...

Hepatology Associates Course - AASLD

www.aasld.org/sites/default/files/documents/2015/Syllabi/HAC Syllabus.pdf

Nov 15, 2015 ... Grant/Research Support: AbbVie, Bristol Myers Squibb, Gilead, Idenix. Rennie M. ... Gary L. Davis, MD, FAASLD (Scientific Program Committee and Governing Board). No conflict of ... Julie Deal. No conflict of .... Chen CJ, et al. JAMA. 2006 ... 0% vs. 5%. Adapted from Sarkar M, Hepatology 2014; 60: 448.

In Vitro Developmental Toxicology Screens - American Chemical ...

pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.5b00458

Nov 6, 2015 ... Julie Panzica-Kelly,. † ... Discovery Toxicology, Bristol Myers Squibb, Pennington , New Jersey 08534, United .... (approximately 10 rats) vs animal requirements for regulatory .... reviewed in 2014 by Lee et al.28,29 Altogether, zebrafish has ..... B., Davis, J., Clee, C., Oliver, K., Clark, R., Riddle, C., Elliot, D.,.

Helpful Resources

Effect of Cognitive Therapy With Antidepressant Medications vs ...

www.ncbi.nlm.nih.gov

Combined treatment enhanced the rate of recovery vs treatment with ADM alone ..... Julie Jacobs, PhD, Cory P. Newman, PhD, and Rita Ryan, PhD (University of ... reports being a consultant to Bristol-Myers Squibb, Cerecor, Inc, Cyberonics, .... Hollon SD, DeRubeis RJ, Shelton RC, et al. ... Beck AT, Freeman A, Davis DD.

Does a GLP-1 receptor agonist change glucose tolerance in patients ...

www.ncbi.nlm.nih.gov

Mar 25, 2014 ... Julie Rask Larsen,<sup>1</sup> Louise Vedtofte,<sup>2</sup> Jens Juul Holst,<sup>3</sup> Peter Oturai .... In a study by Astrup et al, 16 of 90 patients (17.8%) in the liraglutide 1.8 mg group withdrew over the 20-week trial period. .... as well as grants from Bristol-Myers Squibb, Janssen/J&J and Otsuka. ... Hermes E, Nasrallah H, Davis V, et al.

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of ...

www.ncbi.nlm.nih.gov

Julie A. Lemm, <sup>corresponding author</sup> ... BMS-791325 is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus .... were synthesized by Bristol-Myers Squibb, as were HCV reference inhibitors HCV-796, a palm site 2 ..... was seen by Pelosi et al. in GT 1a replicons under selection with BMS-791325 either alone  ...

Selection of Immunostimulant AS15 for Active Immunization With ...

jco.ascopubs.org

Jul 1, 2013 ... ... by enzyme-linked immunosorbent assay as described by Vantomme et al. ..... Alessandro Testori, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, IGEA, ONCOVISION; ... Julie Vandekerckhove coordinated the circulation of the manuscript to all coauthors .... Vantomme V,; Dantinne C,; Amrani N,; et al.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non ...

jco.ascopubs.org

Aug 31, 2015 ... ... MD, University of California, Davis, Comprehensive Cancer Center, 4501 X St, ... DFS favored erlotinib (median, 46.4 v 28.5 months; hazard ratio, 0.61; 95% CI, ..... Boehringer Ingelheim, Merck, Merck Serono, Bristol-Myers Squibb, ... Julie D. Horan ... Strauss GM,; Herndon JE 2nd,; Maddaus MA,; et al.